Drug-Eluting Balloon Catheters

Global Drug-Eluting Balloon Catheters Market to Reach US$935.9 Million by 2030

The global market for Drug-Eluting Balloon Catheters estimated at US$618.8 Million in the year 2024, is expected to reach US$935.9 Million by 2030, growing at a CAGR of 7.1% over the analysis period 2024-2030. Polyurethane, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$532.7 Million by the end of the analysis period. Growth in the Nylon segment is estimated at 8.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$168.6 Million While China is Forecast to Grow at 11.0% CAGR

The Drug-Eluting Balloon Catheters market in the U.S. is estimated at US$168.6 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$194.3 Million by the year 2030 trailing a CAGR of 11.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.6% and 6.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.7% CAGR.

Global "Drug-Eluting Balloon Catheters" Market – Key Trends & Drivers Summarized

Why Are Drug-Eluting Balloon Catheters a Preferred Choice for Vascular Interventions?

The rise in cardiovascular diseases (CVDs) and peripheral artery diseases (PADs) has significantly increased the demand for drug-eluting balloon (DEB) catheters, which offer a less invasive and highly effective alternative to traditional stents. These catheters deliver antiproliferative drugs, such as paclitaxel and sirolimus, directly to the affected arteries, reducing restenosis and minimizing the need for repeat procedures. Unlike drug-eluting stents (DES), which leave behind a permanent implant, DEBs provide a transient yet effective therapeutic solution, ensuring vessel patency without long-term complications like late thrombosis. This makes them particularly beneficial for patients with high risks of bleeding, small vessel disease, or those undergoing repeat interventions. Additionally, the growing preference for minimally invasive procedures, especially among aging populations, has driven the increased adoption of DEB catheters in coronary, peripheral, and arteriovenous fistula (AVF) treatments.

What Innovations Are Enhancing the Effectiveness of Drug-Eluting Balloon Catheters?

Breakthroughs in polymer-free drug coatings, prolonged drug retention strategies, and targeted drug delivery mechanisms are driving improvements in DEB technology. Next-generation hydrophilic carriers, nano-based drug formulations, and bioabsorbable materials have significantly enhanced drug adhesion to arterial walls, ensuring sustained therapeutic effects. Advancements in balloon design and catheter flexibility have also improved the precision and safety of drug delivery, minimizing procedural risks and optimizing outcomes. Furthermore, real-time imaging technologies, including intravascular ultrasound (IVUS) and optical coherence tomography (OCT), are now being integrated into DEB systems, allowing for enhanced visualization and placement accuracy. As regulatory bodies such as the FDA and European Medicines Agency (EMA) approve more indication-specific DEBs, the market is witnessing a surge in clinical trials evaluating their efficacy in diabetic vascular complications, below-the-knee interventions, and dialysis access maintenance.

How Are Regulatory Mandates and Market Trends Driving Adoption?

The increasing regulatory approvals for DEBs across multiple vascular indications have accelerated their global adoption. In Europe, drug-eluting balloon catheters have already gained widespread acceptance as a first-line treatment for in-stent restenosis, while regulatory agencies in the U.S. and Asia-Pacific are expanding approvals for coronary, peripheral, and even neurovascular applications. Hospitals and ambulatory surgical centers are shifting towards catheter-based interventions due to their cost-effectiveness and shorter hospital stays, further fueling demand. Additionally, government initiatives promoting value-based healthcare and outpatient angioplasty procedures have provided a strong push toward DEB utilization. The growing emphasis on hybrid procedures that combine DEBs with bioresorbable scaffolds is also a key market trend, offering better long-term vascular healing outcomes.

What Are the Primary Market Growth Drivers?

The growth in the Drug-Eluting Balloon Catheter market is driven by the increasing burden of cardiovascular and peripheral artery diseases, advancements in drug delivery nanotechnology, and the rising adoption of minimally invasive endovascular procedures. The expansion of DEB applications beyond coronary interventions, particularly in treating diabetic foot ulcers, critical limb ischemia, and hemodialysis access failures, has created new market opportunities. Additionally, rising healthcare expenditures, increasing investments in interventional cardiology, and the shift toward outpatient angioplasty centers are supporting market expansion. With ongoing technological advancements and continuous clinical validation, DEB catheters are poised to become an indispensable component of next-generation vascular care.

SCOPE OF STUDY:

The report analyzes the Drug-Eluting Balloon Catheters market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Material (Polyurethane, Nylon, Others); End-Use (Hospitals & Clinics, Ambulatory Surgery Centers, Catheterization Laboratories)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• Aachen Resonance GmbH
• Aesculap (B. Braun SE)
• Balton Sp. z o.o.
• Bayer AG
• Becton, Dickinson and Company (BD)
• Biosensors International
• Biotronik AG
• Boston Scientific Corporation
• Cardionovum GmbH
• Concept Medical
• Convatec Group
• Cordis (Cardinal Health)
• Districlass Médical
• Eurocor GmbH
• eucatech AG
• iVascular S.L.U.
• Jiangsu Changmei Medtech Co., Ltd.
• Koninklijke Philips N.V.
• Laborie Medical Technologies
• Lepu Medical Technology (Beijing) Co., Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.